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Abstract Originally adapted from the neurosphere assay,
the nonadherent mammosphere assay has been utilized to
assess early progenitor/stem cell frequency in a given
population of mammary epithelial cells. This method
has also been used to measure the frequency of tumor-
sphere initiating cells in both primary mammary tumors
as well as in tumor cell lines. Although, the mammo-
sphere assay has been used extensively in the mammary
gland field, a standard method of quantifying and analyz-
ing sphere growth in this assay has remained undefined.
Here, we discuss the use and benefit of using a limiting
dilution analysis to quantify sphere-forming frequency in
primary mammary epithelial cells grown in nonadherent
conditions.
Keywords Mammosphere . Stem cell . Progenitor cell .
Mammary . Breast . Tumorsphere . Cancer stem cell .
Tumor initiating cell
Abbreviations




SLDA Sphere limiting dilution analysis
MECs Mammary epithelial cells
MMTV Mouse mammary tumor virus promoter
dnIGF-1R Dominant-negative insulin like growth
factor type 1 receptor
WT Wild type
EGF Epidermal growth factor
bFGF Basic fibroblast growth factor
Introduction
Stem cells, their developmental function, and their potential
roles in disease, particularly cancer, have been under intense
investigation over the past decade. The/mammary stem cell
is self-renewing and capable of functionally reconstituting
the entire mammary epithelial cell lineage [1–3]. Mammary
stem cells are potential contenders for the origin and
recurrence of some mammary tumors [1, 4]. Thus, cancer
therapies targeting the subset of cancer stem cells or
tumor initiating cells (TICs) may be most advantageous
in treating these breast cancers and reducing the likelihood
of recurrence [1].
A major hurdle in the mammary stem cell field has been
to develop methods to identify and isolate the small subset
of normal or cancer stem cells in epithelial tissue. Initial
work to classify the stem cell population relied on lineage
tracing and cell division activity in image studies of whole
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tissue and in serial transplantation analyses [5–7]. Subse-
quently, several groups published methods to identify cell
surface markers of mammary gland stem and progenitor
cells using flow cytometry and further linked these protein
markers to in vivo transplantation stem cell activity [8–11].
More advances in the quest to identify and analyze mam-
mary stem cells in vitro came when Dontu and colleagues
described a nonadherent mammosphere assay (for review
see [12] as well as Clarke and colleagues in this issue) which
is an adaptation of the previously established neurosphere
assay [13, 14]. In the original reports on mammospheres,
human mammary epithelial cells were taken from reduction
mammoplasties and grown over multiple passages in non-
adherent conditions [12, 15]. These mammospheres main-
tained tripotentiality when allowed to differentiate in vitro
by growth on either a collagen substratum or embedded in
matrigel® in the presence of the pregnancy hormone,
prolactin [15]. Mammospheres derived from reduction
mammoplasties were found to be enriched for mammary
epithelial stem cells which could produce successful out-
growths after transplantation of as few as 500 mammospheres
into NOD/SCID mice [12]. Moreas and colleagues also
showed that mammospheres derived from primary mouse
mammary epithelial cells were capable of regenerating
complete mammary epithelial trees upon transplantation [16].
The mammosphere assay has been widely utilized to
measure in vitro stem/progenitor cell frequency in normal
primary mammary epithelial cell preparations as well as
frequency of cancer stem cells or TICs derived from malig-
nant mammary tissue [12, 17]. Although the gold standard
stem cell assay is the in vivo transplantation assay, first
described by DeOme et al. [18], the mammosphere assay
has given investigators an in vitro assay that is less time
consuming and more cost effective then the in vivo trans-
plantation assay [18, 19]. Although the mammosphere assay
does not measure actual in vivo stem cell frequency, it can
serve as a relative measure of stem and progenitor cell
frequency in a mixed cell suspension, between varying
experimental groups in vitro. Recently the stem cell field
has been turning to a method popularized initially in immu-
nology research, known as limiting dilution analysis (LDA).
This quantitative approach incorporates the use of a limiting
dilution cell culture assay and established statistical analy-
sis. Several investigators have applied the quantitative LDA
to evaluate the stem cell population in the neurosphere assay
[20, 21]. Methods for quantifying the mammosphere assay
vary within the field. Currently, similar to the neurosphere
assay, sphere number is scored in a multi-sphere culture.
However, this method is prone to subjectivity in sphere
identification as well as culture artifacts (i.e. sphere aggre-
gation/fusion). In the mammary gland field, many in vivo
transplantation studies estimating stem cell frequency have
successfully utilized limiting dilution to measure stem cell
frequency [16, 22]. In this article, we discuss use of the
quantitative LDA for analyzing stem/progenitor cell fre-
quency in secondary and tertiary mammosphere cultures,
and, hereafter, refer to this analysis as a “sphere limiting
dilution analysis” (SLDA). Use of the SLDA has the advan-
tage that it reduces investigator bias, can be used for both
human and mouse mammary epithelial cell populations, and
requires a smaller number of cells than the traditional sphere
assay.
Methods: Sphere Limiting Dilution Analysis
The SLDA operates on the assumption that a single cell can
generate a sphere and that the variation within the experi-
ment from well to well follows a Poisson distribution. (For a
recent review see [23]). When conducting research on a
mixed population of cells such as mammospheres we have
found this analysis useful to evaluate the frequency of
sphere formation as an indication of the presence of stem
or early progenitor cells, and observe it to be consistent with
sphere forming frequency derived from the traditional
sphere counting approach.
To perform the SLDA, the cells are plated into a 96 well
plate over a range of densities from high to low (Fig. 1). The
cells are then given a minimum of 7 days to form spheres.
Figure 1 Schematic showing strategy for limiting dilution plating of
dissociated epithelial cells in 96 well plate for SLDA. The “+” refers to
a well containing one or more spheres and a “–” refers to a well without
any spheres. The figure shows the cells being plated in a limiting
dilution fashion across a 96-well plate. The amount of wells negative
for sphere formation will increase as the plating density decreases as
depicted
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Plating density should be optimized, such that at the highest
density, most wells will be positive for sphere formation,
whereas the lowest density should have less then 1 cell per
well, so the majority of wells are negative for sphere forma-
tion. The SLDA measures the probability of an event hap-
pening, i.e. sphere formation, and assumes that a percentage
of wells at the lowest plating density will be non-responsive
and not form spheres. Therefore, the line plotted from the
experiment should pass through the origin (x00, y00) when
graphing density versus probability of sphere formation or
the fraction of non-responsive wells. To determine the prob-
ability of sphere formation, the wells are scored for the
presence or absence of sphere growth. The natural log
fraction of the negative wells (non-responding) is plotted
on a linear scale versus the density. The density can be
expressed as cells/cm2, cells/mL or cells/well [24]. For this
review and for our experiments we choose cells/cm2
because it does not vary with volume of media in the well.
A linear regression curve is then fit to the data points and the
lower the density at which a population forms a sphere the
higher its frequency for formation, by the equation
P ¼ 1 emD P is probability; m is slope and D is densityð Þ;
arranged Ln 1 Pð Þ ¼ mD where y is Ln 1 Pð Þ
and x is D:
According to the assumed Poisson distribution and as
adopted from Lefkovits [24], the natural log of the fraction
of non-responding wells is linearly proportional to the mean
number of cells with sphere forming potential. When
plotting data using the form of the equation shown here,
the value of x at the y0−1 intercept corresponds to the
frequency of sphere formation and represents 37 % non-
responding wells. This value for different experimental
groups can be compared to evaluate the frequency of sphere
forming cells between varying conditions [24]. The frequency
can be calculated at any point on the line by using the slope
(frequency 0 1/slope) or by using the y0−1 intercept (for
detailed theory see Lefkovits [24]) however for ease of
interpretation we prefer to use the y0−1 intercept for directly
comparing precursor frequency of different populations.
Determining the frequency of sphere formation in culture
assays can provide valuable information for interpreting the
composition of the mixed population of starting cells. If
used on cultures after treatment with a growth factor or
receptor inhibitor, for example, the effects of the treatment
on the percentage of sphere forming cells present in the
population can be evaluated. Similarly, the consequence of
genetic alterations on stem/progenitor cell number can be
evaluated using SLDA. Similar to neurosphere cultures
which enrich for mulitpotential progenitor cells over pas-
sage, the percentage of bipotential progenitor cells in non-
adherent mammosphere cultures increases after several
passages [12, 15]. Thus, using the SLDA on secondary or
tertiary spheres allows one to study a more highly enriched
bipotent progenitor population versus a more heterogeneous
population in the primary spheres.
We have used the SLDA to evaluate sphere formation in
primary mammary epithelial cells (MECs) isolated from
mammary glands expressing an MMTV-dominant negative
insulin-like growth factor-1 receptor (dnIGF-1R) transgene
to determine if defective IGF-1R signaling affected numbers
of mammary stem/progenitor cells. Freshly isolated MECs
were cultured as primary and then secondary mammospheres.
The secondary spheres were dissociated with Accutase™ for
5 min at 37 °C and mechanically triturated until a single cell
suspension was achieved. Cells were then plated at densities
ranging from 1000 to 0.00012 cells (optimal range of cells for
the SLDA in our mammosphere conditions; should be opti-
mized for different cell populations and investigator condi-
tions) across two 96 well plates in 200 μl of PRO-N media
with 8 replicates for each dilution and then evaluated for
tertiary sphere formation after 7 days in culture. We scored
each well for the absence (−) or presence (+) of sphere growth
to determine the fraction of negative wells (Fig. 1, schematic).
The plot shows natural log transformation for the fraction of
non-responding wells (y-axis) versus plating density (x-axis)
(Fig. 2). As discussed, the probability of forming a sphere is
determined by the x intercept (cell density) when y0−1. The
sphere forming frequency of the dn-IGF-1R tertiary spheres

































Figure 2 SLDA comparing stem cell frequency in tertiary spheres
between dnhIGF-1R and FVB (WT) primary mammary epithelial cells
grown in PRO-N media in 96 well ultra-low adherent plates (Corning).
Plating density ranges from 1000 to 0.00012 cells/well, which was
converted to cells/cm2 in this graph. Tertiary sphere forming frequency
for dn-IGF-1R is 1 in 526 cells versus 1 in 127 cells for the wild type
control. PRO-N media contained EGF/bFGF (20 ng/ml), bovine Insu-
lin 25 μg/ml (Sigma), d-Biotin 10 ng/ml (Sigma), Progesterone 20 nM
(Sigma), Putrescine 100 μM (Sigma), Selenium 5 ng/ml (Sigma), Apo-
transferrin 50 μg/ml (Sigma), Gentamycin 50 μg/ml (Invitrogen-
Gibco), Hydrocortisone 0.5 μg/ml (Sigma). Linear (fvb) and Linear
(dn) indicate best fit line for linear regression analysis
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capable of forming a tertiary sphere compared to the wild-type
control cells that had a tertiary sphere forming frequency of 1
in 127 cells. Thus, we conclude that IGF-1R signaling is
required for survival and/or sphere formation and may there-
fore be important for stem and/or progenitor cell growth. This
result is consistent with sphere growthmeasures using a visual
counting method in a multi-sphere culture.
Discussion
Although, it is clear that mammospheres are enriched for
multipotent cells, it remains somewhat ambiguous as to
what passage number (i.e. primary, secondary, or tertiary)
the spheres should be analyzed for the number of stem/
multipotent progenitor cells in the population. It is generally
accepted that number of spheres formed is equivalent to the
combined number of stem and progenitors in a given pop-
ulation of mammary epithelial cells. The passage number
(i.e. primary, secondary, etc.) and plating density, however,
at which the mammospheres are analyzed has varied be-
tween investigators and could have an influence on the
number of stem and progenitor cells present. Another limi-
tation of the sphere assay relates to whether this assay
properly identifies the frequency of in vivo quiescent stem
cells as opposed to measuring cells that adapt or can act as a
proliferating mammary stem cell in vitro. The validity of
using the sphere assay as a functional test to measure fre-
quency of in vivo stem cells was recently addressed in a
review considering the correlation between neurosphere
forming cells and number of neural stem cells in vivo [25].
Pastrana et al. concluded that the neurosphere assay does not
properly identify numbers of quiescent neural stem cells in
vivo. Furthermore, until these quiescent stem cells can be
definitively elucidated using cell markers, the frequency of
these cells in vivo will remain an enigma. The same caveats
are applicable for the mammosphere assay; it is still unclear
whether the mammosphere assay truly identifies quiescent
stem cells in the mammary gland. Also, multi-potential
progenitor cells can give rise to sphere growth as well as
stem cells. In addition, although stem cell growth and sur-
vival factors such as wnt and hedgehog have been identi-
fied, optimal growth conditions have not been standardized
for mammosphere growth; therefore, the mammosphere
assay is likely not a true measure of physiological stem
cell frequency. Mammosphere cultures, like neurosphere
cultures, however, do enrich for epithelial cells that
behave like mammary stem cells in vitro and are capa-
ble of forming all three lineages when transplanted into
cleared fat pads [16].
Within the limitations of the mammosphere assay, by
standardizing methods in quantifying the mammosphere
assay using the SLDA, it is possible to reduce bias between
experiments and between investigators. Furthermore, using
the SLDA to quantify mammospheres in secondary and
subsequent passages, due to their known enrichment for
multipotent cells, will allow for greater confidence in inter-
pretation that the calculated number of sphere forming cells
correlates with number of multipotential progenitors or stem
cells. The use of the SLDA on primary mammospheres
should be avoided if possible when measuring multipotent
cell frequency because primary cultures are more heteroge-
nous then are secondary and tertiary sphere cultures as
discussed by Dontu and colleagues (2005), however, in
circumstances where a genetic alteration or treatment con-
dition prevents subsequent passaging of mammospheres, it
would still be useful to assess primary sphere forming
frequency. An example of this was seen with constitutive
activation of smoothened in mammary epithelial cells [16].
Because the SLDA takes multiple plating densities (from
clonal to higher densities) into account, it allows for a more
comprehensive method of quantifying sphere formation and
sphere size in a given population of cells. Sphere size may
be a reflection of a mitogenic response to specific treatment
conditions and progenitor expansion, however, due to
sphere aggregation, emphasis has been placed on analyzing
sphere size at clonal densities [25]. In the SLDA, sphere size
can accurately be evaluated at the lower densities (i.e. 1≤
cell per well). In summary, the SLDA is an advantageous
tool in quantifying sphere forming frequency in a population
of mammary epithelial cells. The SLDA does not require a
large amount of cells so can be utilized when sample quan-
tities are limited. Due to low density plating, it also reduces
problems of cell aggregation. Finally, the SLDA method
reduces investigator bias and can lead to a more standard
method for quantifying stem/progenitor cell frequency in
mammospheres.
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